Novo Nordisk

Novo sticks to oral semaglutide amid rising demand for injectables

Novo Nordisk will strengthen its oral semaglutide portfolio led by Rybelsus while cutting Wegovy injection prices by up to 37% to improve accessibility and expand its market in India

Novo Nordisk cuts weight-loss drug Wegovy prices by up to 37% in India

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

Novo Nordisk, Emcure Pharma to launch weight-loss drug under new brand

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited

Pfizer signs deal with Metsea after bidding war with Novo Nordisk

The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity

India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

Ozempic maker Novo Nordisk to cut 9,000 job to save $1.3 billion annually

Novo Nordisk will cut 11.5 per cent of its workforce to save costs and streamline operations as competition rises and sales of Wegovy and Ozempic slow, especially in the US market

Will this court fight make the world's hottest weight-loss drug cheaper?

Indian pharma takes Novo Nordisk to court over patents that keep Wegovy and Ozempic out of reach - could this slash prices for millions of patients?

Denmark aims to build world's most powerful quantum computer, Magne

Microsoft, which has its largest quantum lab in Denmark, will provide software and Atom Computing will build the quantum computer

IIM Ahmedabad, Novo Nordisk India partner to boost obesity care ecosystem

The Indian Institute of Management Ahmedabad on Wednesday said it has signed an agreement with Novo Nordisk India to strengthen the obesity care ecosystem in the country for five years till 2030. The memorandum of understanding, inked on Tuesday, aims to strengthen the healthcare ecosystem in India through a multi-dimensional approach focused on non-communicable diseases (NCDs), especially obesity, the Indian Institute of Management Ahmedabad (IIMA) said in a statement. "This collaboration with Novo Nordisk India brings together healthcare and public policy, two domains where data and research can enable lasting change. At IIMA, we aim to apply our academic rigour to generate actionable insights for policymakers, healthcare professionals, and communities tackling non-communicable diseases like obesity," IIM Ahmedabad Director Professor Bharat Bhasker said. As a part of this collaboration, Novo Nordisk India (NNIPL) and IIMA will co-develop and implement impactful programmes under ..

Demand for obesity drugs soars in India as Lilly, Novo jostle for mkt share

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst three globally for high obesity rates

Obesity drug race begins: Wegovy launches in India | Novo Nordisk | Weight loss drug | Pharma sector

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly’s launch of Mounjaro just 3 months ago.

Novo Nordisk launches blockbuster weight-loss drug Wegovy in India

The 1.75 mg and 2.4 mg doses will be priced at ₹24,280, and 2.4 mg will be priced at ₹26,050 for a month

Why Ozempic maker Novo Nordisk is losing its lead in weight-loss drugs

The Danish drugmaker led the obesity revolution with Ozempic and Wegovy but now lags Eli Lilly in efficacy, trials, and strategy in a $150-bn market

Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

Drug compounders sue FDA over removal of Wegovy, Ozempic from shortage list

The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was arbitrary and capricious

In weight loss battle, Novo and Lilly face offensive from licenced copies

Since Novo's blockbuster Ozempic diabetes treatment was approved in the United States in 2017, regulators have greenlighted 22 medicines containing its main ingredient in Bangladesh, Laos, Russia

Novo Nordisk India execs urge early Wegovy launch as rival Eli Lilly looms

Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade

Novo Nordisk expects high demand for obesity drugs in India: Country head

The company is still 'evaluating' the price of the drug, but is confident that the price-sensitive Indian population will be able to afford it, Novo's India Managing Director Vikrant Shrotriya said

Novo Nordisk pares 2024 profit outlook amid competition from Eli Lilly

The Danish company lowered its forecast for operating profit growth this year to between 20% and 28% in local currencies, compared to its previous forecast of 22% to 30%